Lasa Supergenerics Limited Asset Resilience Ratio
Lasa Supergenerics Limited asset resilience ratio. Lasa Supergenerics Limited (LASA) has an Asset Resilience Ratio of 1.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Lasa Supergenerics Limited to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lasa Supergenerics Limited (2017–2025)
Asset resilience ratio of Lasa Supergenerics Limited from 2017 to 2025. This chart shows how Lasa Supergenerics Limited's Asset Resilience Ratio has changed over time. Read Lasa Supergenerics Limited (LASA) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lasa Supergenerics Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LASA current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs4.08 Million | 0.57% |
| Short-term Investments | Rs4.08 Million | 0.57% |
| Total Liquid Assets | Rs8.16 Million | 1.14% |
Asset Resilience Insights
- Limited Liquidity: Lasa Supergenerics Limited maintains only 1.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Lasa Supergenerics Limited Industry Peers by Asset Resilience Ratio
Compare Lasa Supergenerics Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Lasa Supergenerics Limited Asset Resilience Ratio by Year (2017–2025)
Lasa Supergenerics Limited asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Lasa Supergenerics Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 1.01% | Rs10.30 Million ≈ $111.39K |
Rs1.02 Billion ≈ $10.98 Million |
-0.16pp |
| 2024-03-31 | 1.18% | Rs17.75 Million ≈ $192.00K |
Rs1.51 Billion ≈ $16.32 Million |
-0.64pp |
| 2023-03-31 | 1.81% | Rs29.69 Million ≈ $321.10K |
Rs1.64 Billion ≈ $17.72 Million |
-4.07pp |
| 2022-03-31 | 5.88% | Rs123.02 Million ≈ $1.33 Million |
Rs2.09 Billion ≈ $22.62 Million |
+5.34pp |
| 2021-03-31 | 0.54% | Rs11.23 Million ≈ $121.40K |
Rs2.08 Billion ≈ $22.48 Million |
-66.57pp |
| 2020-03-31 | 67.11% | Rs1.56 Billion ≈ $16.84 Million |
Rs2.32 Billion ≈ $25.09 Million |
+66.95pp |
| 2019-03-31 | 0.16% | Rs4.21 Million ≈ $45.51K |
Rs2.58 Billion ≈ $27.96 Million |
-0.76pp |
| 2018-03-31 | 0.92% | Rs26.35 Million ≈ $284.94K |
Rs2.87 Billion ≈ $31.01 Million |
-0.04pp |
| 2017-03-31 | 0.96% | Rs21.82 Million ≈ $236.03K |
Rs2.28 Billion ≈ $24.68 Million |
-- |
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more